1143 related articles for article (PubMed ID: 30120962)
21. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
22. Amyloid-beta, tau, and dementia.
Takashima A
J Alzheimers Dis; 2009; 17(4):729-36. PubMed ID: 19542626
[TBL] [Abstract][Full Text] [Related]
23. Aged chimpanzees exhibit pathologic hallmarks of Alzheimer's disease.
Edler MK; Sherwood CC; Meindl RS; Hopkins WD; Ely JJ; Erwin JM; Mufson EJ; Hof PR; Raghanti MA
Neurobiol Aging; 2017 Nov; 59():107-120. PubMed ID: 28888720
[TBL] [Abstract][Full Text] [Related]
24. Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease.
Pooler AM; Polydoro M; Maury EA; Nicholls SB; Reddy SM; Wegmann S; William C; Saqran L; Cagsal-Getkin O; Pitstick R; Beier DR; Carlson GA; Spires-Jones TL; Hyman BT
Acta Neuropathol Commun; 2015 Mar; 3():14. PubMed ID: 25853174
[TBL] [Abstract][Full Text] [Related]
25. Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer's disease.
Takahashi RH; Nagao T; Gouras GK
Pathol Int; 2017 Apr; 67(4):185-193. PubMed ID: 28261941
[TBL] [Abstract][Full Text] [Related]
26. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
[TBL] [Abstract][Full Text] [Related]
27. Role of tau protein in Alzheimer's disease: The prime pathological player.
Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B
Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025
[TBL] [Abstract][Full Text] [Related]
28. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease.
Kazim SF; Iqbal K
Mol Neurodegener; 2016 Jul; 11(1):50. PubMed ID: 27400746
[TBL] [Abstract][Full Text] [Related]
29. Role of insulin resistance in Alzheimer's disease.
Cai Z; Xiao M; Chang L; Yan LJ
Metab Brain Dis; 2015 Aug; 30(4):839-51. PubMed ID: 25399337
[TBL] [Abstract][Full Text] [Related]
30. Recent update on the heterogeneity of the Alzheimer's disease spectrum.
Jellinger KA
J Neural Transm (Vienna); 2022 Jan; 129(1):1-24. PubMed ID: 34919190
[TBL] [Abstract][Full Text] [Related]
31. Immunological aspects and anti-amyloid strategy for Alzheimer's dementia.
Liščić RM
Arh Hig Rada Toksikol; 2013 Dec; 64(4):603-8. PubMed ID: 24384767
[TBL] [Abstract][Full Text] [Related]
32. Monitoring synaptic pathology in Alzheimer's disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives.
Lista S; Santos-Lozano A; Emanuele E; Mercuri NB; Gabelle A; López-Ortiz S; Martín-Hernández J; Maisto N; Imbimbo C; Caraci F; Imbimbo BP; Zetterberg H; Nisticò R
Mol Psychiatry; 2024 Mar; 29(3):847-857. PubMed ID: 38228892
[TBL] [Abstract][Full Text] [Related]
33. First-in-Rat Study of Human Alzheimer's Disease Tau Propagation.
Smolek T; Jadhav S; Brezovakova V; Cubinkova V; Valachova B; Novak P; Zilka N
Mol Neurobiol; 2019 Jan; 56(1):621-631. PubMed ID: 29770957
[TBL] [Abstract][Full Text] [Related]
34. Astrocyte and Alzheimer's disease.
Cai Z; Wan CQ; Liu Z
J Neurol; 2017 Oct; 264(10):2068-2074. PubMed ID: 28821953
[TBL] [Abstract][Full Text] [Related]
35. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
[TBL] [Abstract][Full Text] [Related]
36. Minimalistic in vitro systems for investigating tau pathology.
Hallinan GI; Pitera AP; Patel P; West J; Deinhardt K
J Neurosci Methods; 2019 May; 319():69-76. PubMed ID: 30278185
[TBL] [Abstract][Full Text] [Related]
37. Targeting Abeta and tau in Alzheimer's disease, an early interim report.
Golde TE; Petrucelli L; Lewis J
Exp Neurol; 2010 Jun; 223(2):252-66. PubMed ID: 19716367
[TBL] [Abstract][Full Text] [Related]
38. Histopathological and immunohistochemical comparison of the brain of human patients with Alzheimer's disease and the brain of aged dogs with cognitive dysfunction.
Yu CH; Song GS; Yhee JY; Kim JH; Im KS; Nho WG; Lee JH; Sur JH
J Comp Pathol; 2011 Jul; 145(1):45-58. PubMed ID: 21256508
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA in Alzheimer's disease revisited: implications for major neuropathological mechanisms.
Dehghani R; Rahmani F; Rezaei N
Rev Neurosci; 2018 Feb; 29(2):161-182. PubMed ID: 28941357
[TBL] [Abstract][Full Text] [Related]
40. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.
Prvulovic D; Hampel H
Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
